DIGNITANA

DIGNITANA PRESERVING DIGNITY OF UFE Chairman: CEO: Listing (ticker): Market capitalisation: Website: Semmy Ri.ilf Jan Richardsson Nasdaq First North (DIGN) SEK 320 m (Price SEK 19, April 4. 2016) www.dignitana.com Strictly confidential STOCKHOLM CORPORATE FINANCE ABOUT DIGNITANA Dignitana AB (pub,' ("Dignitana" or the "Company"), founded 2007, is a world leader in medical scalp cooling technology and the manufacturer of the DigniCap scalp cooling system. DigniCap reduces hair loss when patients are going through chemotherapy and has been used world- wide for many years. Approximately 400 systems have been delivered worldwide and more than 15,000 patients have been treated. December 2015 represented a significant breakthrough for the company when FDA clearance for the Dignicap system was received. The DigniCap scalp cooling system was cleared for use in women with breast cancer in the U.S. To date, contracts have been signed with ten cancer centers across the United States (March-16). Dignitana is listed on the NASDAQ First North Stock Exchange since 2011. BUSINESS CONCEPT Dignitana's business concept is to develop, produce and market scalp- cooling technology. THE MARKET Breast cancer is the most common malignancy in women worldwide. Although the majority of women will survive the disease, treatment often includes chemotherapy. Hair loss remains an almost universal side effect of chemotherapy and is rated by breast cancer patients as one of the most distressing side effects of treatment, affecting qual- ity of life, return to work, and self-image. Some clinical studies indi- cate that as many as 5% of the patients refuse chemo therapy in fear of hair loss. Approximately 230,000 new breast cancer patients are diagnosed per year in the United States of which approximately 60% can use Digni- Cap. Each patient receives on average 5 cycles of chemotherapy. The market potential for this particular segment in the USA is approx. 700 000 treatments per year, or about 5400 m per year. BUSINESS MODEL The DigniCap system is sold to distributors as a stand-alone system in most countries in Europe and in Asia. Sysmex Europe GmbH is responsi- ble for sales in the major European markets. Konica Minolta Medical & Graphic Inc. is responsible for the largest Asian markets, such as China, Japan and India. U.S. is expected to be the largest market for the Company and represents 50% of the total medical device market worldwide. The Company has, since the FDA clearance, established its own organization in the U.S with headquarters in Dallas. The company has been able to hire a group of scalp cooling professionals who have experience using manual scalp cooling techniques and significant contacts within the oncology commu- nity. The business model in the U.S. is to lease the system to the facility and also receive payment per treatment. Standard contract: two-year lease at 600-1,000 USD/month plus 175.350 USD/treatment. PATENT Currently, the Company holds two patents; sensors in the cap and split cap functionality. Separate Coolant Circuits - patent expires in 2034. Temperature sensors - patent expires this year. INVESTMENT CASE • Breakthrough in December 2015 - FDA clearance, own or- ganization and new business model in USA, "paid per treat- ment" with high margins (three times production cost 12 year). Ten contracts signed in the USA as of end of March. • Only the US market is valued at approx. 5400 m yearly. • First mover advantage - Supplier of the most advanced auto- mated cooling caps in the world. • Excellent new management with proven track record from the medical device sector - Chairman Semmy Waif has a long experience from the medtech-sector. CEO Jan Richardsson previously VP sales Nederman with proven track record from developing sales organizations. In the USA Bill Cronin is the CEO of the US office and is also a large shareholder and has significant scalp cooling experience. • Large media coverage in the USA since the launch drives market demand from patients and clinics - Prevention of hair loss through scalp cooling contributes to the patient's well-being and quality of life. In the U.S. patients will re- quest and demand clinics to provide DigniCap. FINANCIAL INFORMATION During 2015 the main focus of the Company has been to receive the FDA- approval as well as build up an organization. These investments have ob- viously affected the sales activities during the year. Dignitana (KSEK) Total revenues Full year 2015 (Group) Full year 2014 (AB) 801 21 219 Net profit after financial items -16 569 -10914 Cash and bank balances 19 042 1094 OWNERSHIP STRUCTURE As of 31 Dec. 2015, the Company had some 2,000 shareholders. Shareholder on 31 December 2015 Number of Shares Percentage of capital and orates Euzosund 3 750222 22.4% AViati Pension 2 112 505 12.6% C3 Dente Partners LP 1 653 551 9.9% Nordnet Pennon 6417% 3,4% Green Pads & Golf Ventures 629 397 3,4% ML, Pierce, Fenner & Smith Inc. 371 064 2,2% Semmy RUN 335 079 2,0% Citibank, CENT-Charles Schwab. Newyork 254 233 1,5% Citibank, CHIDN-LIIIS, London 152 000 0,9% William Cronin 147 021 0,9% Others 6717005 40.1% Sum 16774 164 100,016 SHARE PRICE, PAST 12 MONTHS a EalA INiam Stodhcim Corporate Finance AB, Engelbrettscian 1, 114 29 Stockholm Tel Fax Aviv, .stockholmcmy.se 'Ma ExecutiveSummary provides a summary of the Company on./ and does not represent a complete presentation of the Company or the Milt% on which 4 operates. This Executor* Summary h bunion Somalian provided by the Company. It is up to investors to performan independent audt. SCF is not responsible for any direct or inerect losses oe damages suffered In connection with an investment in the company. EFTA01114097